About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Back to clinical trial search

UNKNOWNNCT05840861

Using 18F-FPEB PET to Identify mGLUR5 Availability in Affective Disorders

Evidence suggests that mGLUR5 availability may play a key role in the biology of mood disorders. This study aimed to investigate the changes in metabotropic glutamate receptor 5 (mGLUR5) availability ...

Lead sponsor: Central South University•1 locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Contacts

Yan Zhang, MD PhD

CONTACT

13807315182 yan.zhang@csu.edu.cn

Sponsors

Lead Sponsor

Central South University

Age

18 - 35 years

Sex

ALL

Healthy Volunteers

Yes

Inclusion Criteria

•Meet DSM-V criteria for a current depressive episode.
•Being first-episode patients who were medication-naïve;
•Score \>17 on 17-item Hamilton Depression Rating Scale (HDRS), score \>22 on Montgomery-Asberg Depression Rating Scale (MADRS), and score \<6 on Young Mania Rating Scale (YMRS).
•Age 18 to 35.
•Able to give written informed consent.

Exclusion Criteria

•Have a current or past significant medical, neurological or metabolic disorder or head injury
•Have active, significant suicidal ideation or past suicide attempts
•Have implanted metallic devices or any MR contraindications
•Are women who are pregnant or breastfeeding
•Met DSM-5 criteria for substance use disorder
•Met DSM-5 criteria for any current Axis I diagnosis (except Generalized Anxiety Disorder)
•Are MDD patients present with delusions and/or hallucinations

Related studies

Research on the Efficacy and Safety of Targeted Suprachiasmatic Nucleus Electrical Stimulation for Improving Metabolic Disorders in Patients With Stable Bipolar Disorder Comorbid With Obesity

NCT07589647 · Bipolar Disorder (BD)

RECRUITINGPhase 2

Correcting Circadian Rhythms to Breakthrough in Bipolar Disorder

NCT06226025 · Bipolar Disorder, Delayed Sleep-Wake Phase Disorder

RECRUITINGPhase 3

Ketamine Augmentation of ECT in Treatment-Resistant Depression

NCT07088380 · Major Depressive Disorder, Treatment Resistant Depression

RECRUITINGPhase 2

Lemborexant for the Treatment of Residual Insomnia in Major Depressive Disorder (MDD)

NCT06843187 · Major Depressive Disorder(MDD), Insomnia Comorbid to Psychiatric Disorder

RECRUITINGPhase 3

"A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder"

NCT06564818 · Major Depressive Disorder

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: August 14, 2023Terms

Trial snapshot

StatusUNKNOWN

Phase—

Enrollment59

Start dateNov 2020

Last updatedAug 14, 2023

Condition

Major Depressive Disorder Bipolar Disorder

Locations shown

Mental Health Institute & Faculty of Psychiatry of The Second Xiangya Hospital, Central South University

Changsha, Hunan

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: August 14, 2023Data synced to Clareo: May 25, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions